ReNeuron Group plc Presentation of positive pre-clinical data (0080T)
October 09 2017 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 0080T
ReNeuron Group plc
09 October 2017
AIM: RENE 9 October
2017
ReNeuron Group plc
ReNeuron presents positive pre-clinical data with its ExoPr0
exosome cancer therapy candidate at major scientific conference
Data show that ExoPr0 can inhibit proliferation in a diverse
panel of cancer cell lines
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based
global leader in the development of cell-based therapeutics, is
pleased to announce that it will today be presenting further new
positive pre-clinical data relating to its ExoPr0 CTX cell-derived
exosome therapy candidate at the American Society for Exosomes and
Microvesicles (ASEMV) 2017 Annual Meeting in San Francisco, a
leading scientific conference.
The data reveal that a number of tumour-derived cell lines
showed a significant reduction in proliferation when treated with
ExoPr0 and provide important proof-of-concept data indicating that
ReNeuron's ExoPr0 exosome therapy candidate could have broad
applicability as an anti-cancer therapy.
Professor Karol Sikora, a leading UK-based oncologist and an
adviser to ReNeuron, said:
"This is a novel and completely unexplored strategy for
selectively targeting the growth of cancer cells. Its effectiveness
against a range of cells from different tumour types is intriguing
and warrants further investigation. We need to understand the
molecular mechanisms involved and how to enhance them. This work
has the potential to uncover a whole new area in cancer
therapeutics."
Dr Randolph Corteling, Head of Research at ReNeuron, said:
"We are very encouraged by the data being presented at the ASEMV
2017 conference relating to our ExoPr0 exosome therapy candidate.
These latest findings relating to the anti-cancer potential of
ExoPr0 builds upon data presented earlier this year relating to the
characterisation and scale-up potential of ExoPr0 and the ability
to deliver ExoPr0 by local or systemic administration to target
specific organs. Taken together, this already substantial body of
pre-clinical evidence clearly demonstrates the potential of this
novel therapeutic platform to target multiple diseases, including
cancer."
In a poster and platform presentation at the conference,
ReNeuron researchers will describe studies undertaken in
collaboration with the Company's academic collaborators at Queen
Mary University London. The studies were supported by a grant from
the UK's innovation agency, Innovate UK, and utilised a
high-throughput approach to screen a panel of cancer cell lines for
response to ExoPr0 treatment. In a subset of cell lines, the
response was due to the induction of apoptosis (cell death). In a
separate group of cell lines, induction of senescence was observed
in response to ExoPr0. These effects were noted to be
dose-dependent, with higher doses of ExoPr0 eliciting a greater
effect. Further work to understand the mechanism of action of these
effects is ongoing.
ReNeuron has identified the potential of ExoPr0 as both a novel
therapeutic candidate and as a drug delivery vehicle, based on
earlier research to demonstrate the ability of ExoPr0 to modulate
fibroblasts, immune cells and cancer cell lines in vitro. This
earlier work, together with the new pre-clinical findings described
above, suggest that there is significant potential to develop
ExoPr0 for the treatment of multiple diseases, including solid
tumours.
The ASEMV 2017 meeting is taking place in San Francisco, 8-12
October 2017. Further information about the meeting can be found at
www.asemv.org/meetings
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke, for critical limb
ischaemia and for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise lack
adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCMLBITMBTMMAR
(END) Dow Jones Newswires
October 09, 2017 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024